Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Epilepsy 1Advanced Solid Tumors 1

Interventions

Sirolimus 4LY3295668 erbumine 3Everolimus 3Medical Marijuana 2Anticonvulsants 2ziprasidone 1perampanel 1enzalutamide 1clevidipine 1brivaracetam 1Zolpidem 1Warfarin 1Vigabatrin 1Vecuronium Bromide 1Vancomycin 1Tranexamic Acid 1Topotecan 1Tobramycin 1Therapeutic Touch 1Temozolomide 1TAS-119 1Surgical Procedures, Operative 1Sulfasalazine 1Spironolactone 1Sevoflurane 1Sevelamer 1Saline Solution 1Rocuronium 1Registries 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epilepsy × TAS-119 × Clear all
NCT02134067 2024-09-05

Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Terminated
30 enrolled

Epilepsy, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡